The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: Results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS)

Diabetes Care

Volumn 26, Issue 2, 2003, Pages 349-354

  Henricsson, Marianne ^a   Nyström, Lennarth ^b   Blohmé, Göran ^c   Östman, Jan ^d   Kullberg, Carin ^e   Svensson, Maria ^b   Schölin, Anna ^f   Arnqvist, Hans J ^e   Björk, Elisabeth ^f   Bolinder, Jan ^d   Eriksson, Jan W ^b   Sundkvist, Göran ^g  

^a HELSINGBORG HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; COHORT ANALYSIS; DIABETIC RETINOPATHY; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; POPULATION RESEARCH; SWEDEN; BODY MASS; COMPARATIVE STUDY; HOSPITALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; TIME;

ADOLESCENT; ADULT; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; PREVALENCE; SEVERITY OF ILLNESS INDEX; SWEDEN; TIME FACTORS;

EID: 0038525261     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.2.349     Document Type: Article

References (34)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
4. Landin-Olsson M, Karlsson FA, Lernmark Å, Sundkvist G, the Diabetes Incidence Study in Sweden Group: Islet cell and thyreogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the Diabetes Incidence Study in Sweden. Diabetes 41:1022-1027, 1992
5. Littorin B, Sundkvist G, Hagopian W, Landin-Olsson M, Lernmark Å, Östman J, Arnqvist HJ, Blohmé G, Bolinder J, Eriksson JW, Lithner F, Scherstén B, Wibell L: Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment: a cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care 22:409-412, 1999
6. Östman J, Arnqvist HJ, Blohmé G, Lithner F, Littorin B, Nyström L, Sandström A, Scherstén B, Wall S, Wibell L: Epidemiology of diabetes mellitus in Sweden: results of the first year of a prospective study in the population age group 15-34 years. Acta Med Scand 220:437-445, 1986
7. Klein R, Klein BEK, Magli YL, Brothers RJ, Meuer SM, Davis MD: An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183-1187, 1986
8. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107:237-243, 1989
9. Diabetic Retinopathy Study Research Group: Report VII: A modification of the Airlie House classification of diabetic retinopathy. Invest Ophthalmol Vis Sci 21:210-226, 1981
10. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
11. Arnqvist HJ, Littorin B, Nyström L, Scherstén B, Östman J, Blohmé G, Lithner F, Wibell L: Difficulties in classifying diabetes at presentation in the young adult. Diabet Med 10:606-613, 1993
12. Borg H, Fernlund P, Sundkvist G: Measurement of antibodies against glutamic acid decarboxylase 65 (GADA): two new 1251 assays compared with [35S]GAD 65-ligand binding assay. Clin Chem 43:779-785, 1997
13. Borg H, Fernlund P, Sundkvist G: Protein tyrosine phosphatase-like protein IA2-antibodies plus glutamic acid decarboxylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus. Clin Chem 43:2358-2363, 1997
14. 1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 32:1867-1872, 1986
15. Gottsäter A, Landin-Olsson M, Fernlund P, Gullberg B, Lernmark Å, Sundkvist G: Pancreatic beta-cell function evaluated by intravenous glucose and glucagon stimulation: a comparison between insulin and C-peptide to measure insulin secretion. Scand J Clin Lab Invest 52:631-639, 1992
16. Littorin B, Sundkvist G, Scherstén B, Nyström L, Arnqvist HJ, Blohmé G, Lithner F, Wibell L, Östman J: Patient administrative system as a tool to validate the ascertainment in the diabetes incidence study in Sweden (DISS). Diabetes Res and Clin Pract 33:129-133, 1996
17. Palmberg P, Smith M, Waltman S, Krupin T, Singer P, Burgess D, Wendlant T, Achtenberg J, Cryer P, Santiago J, White N, Kilo C, Daughaday W: The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 88:613-618, 1981
18. Moss SE, Klein R, Kessler SD, Richie KA: Comparison between ophthalmoscopy and fundus photography in determining the severity of diabetic retinopathy. Ophthalmology 92:62-67, 1985
19. DCCT Research Group: The effect of intensive diabetes treatment on the progression of retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 113:36-49, 1995
20. Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR: Microaneurysms in the development of diabetic retinopathy (UK Prospective Diabetes Study Group). Diabetologia 42:1107-1112, 1999
21. The EURODIAB IDDM Complications Study Group: Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 37:278-285, 1994
22. Olsen BS, Johannesen J, Sjölie AK, Borch-Johnsen K, Hougaard P, Thorsteinsson B, Pramming S, Marinelli K, Mortensen HB, the Danish Study Group of Diabetes in Childhood: Metabolic control and the prevalence of microvascular complications in young Danish patients with type 1 diabetes mellitus. Diabet Med 16:79-85, 1999
23. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy II: prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520-526, 1984
24. Malone JI, Morrison AD, Pavan PR, Cuthbertson DD: Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the Diabetes Control and Complications Trial. Diabetes Care 24:522-526, 2001
25. American College of Physicians, American Diabetes Association, American Academy of Ophthalmology: Screening guidelines for diabetic retinopathy. Clinical Guideline. Ophthalmology 99:1626-1628, 1992
26. The Swedish Council on Technology Assessment in Health Care: Diabetic Retinopathy: The Value of Early Detection. Stockholm, Sweden, SBU, 1993
27. Keen H, Lee ET, Russell D, Miki E, Bennett PH, Lu M, the WHO Multinational Study Group: The appearance of retinopathy and progression to proliferative retinopathy: the WHO multinational study of vascular disease in diabetes. Diabetologia 44 (Suppl. 2):S22-S30, 2001
28. Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815-819, 1992
29. Kullberg CE, Bergstrom A, Dinesen B, Larsson L, Little RR, Goldstein DE, Arnqvist HJ: Comparisons of studies on diabetic complications hampered by differences in GHb measurements. Diabetes Care 19:726-729, 1996
30. Nilsson A, Blohmé G, Fritz T: National Diabetes Registry: a teaching pedagogical instrument for quality insurance [in Swedish with English summary]. Lakartidningen 98:314-320, 2001
31. Klein R, Klein BEK, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy XIV (1994) ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 112:1217-1228, 1994
32. Zhang L, Krzentowski G, Albert A, Lefebvre PJ: Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24:1275-1279, 2001
33. Dorchy H, Clae C, Verougstraet C: Risk factors of developing proliferative retinopathy in type 1 diabetic patients. Diabetes Care 24:789-799, 2002
34. Uckaya G, Ocata M, Bayraktar Z, Erten V, Bingol N, Ozdemir IC: Is leptin associated with diabetic retinopathy? Diabetes Care 23:371-376, 2000